What is more, these measures have typically been developed for use in patients with dementia but there may be significant differences in the things that matter to the individual along the disease spectrum in terms of what “good” brain health looks like ( 12 ), making many of these outcome measures not applicable for use at preclinical or prodromal stages of Alzheimer’s disease and related dementias (ADRD).
← all excerpts
Towards a lifelong personalized brain health program: empowering individuals to define, pursue, and monitor meaningful outcomes.
1
—
—